Senior Director Clinical Development
Annexon BiosciencesHighlight
Summary
About the Role
About You
- MD or PhD in Neurology, Neuroscience, or a related field.
- Over 10 years of experience in clinical development, focusing on CNS-related indications.
- Proven leadership in designing, managing, and executing clinical trials from early phase through late-stage development.
- Demonstrated experience in leading clinical development teams at a senior or executive level in a high-growth biotech or pharmaceutical environment.
- In-depth knowledge of global regulatory requirements and clinical development processes.
- Exceptional leadership, strategic thinking, and communication skills.
- Ability to work effectively in a fast-paced environment and manage multiple priorities.
- Strong analytical and problem-solving skills.
- Experience with regulatory submissions and clinical trial oversight in a biotech or pharmaceutical setting.
- Familiarity with emerging trends in neurology, including cutting-edge therapeutic modalities.
Benefits
- Flexible work schedules and remote opportunities.
- Shuttle service from BART, CalTrain, and the Ferry.
- Competitive base salary and equity participation.
- Comprehensive health benefit package including medical, dental, vision, 401(k), and flexible spending plans.
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.